Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
| ▸ | FLT4 | P35916 | 1/20 | 0.67 |
| ▸ | KDM1A | O60341 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | MET | P08581 | 2/20 | 0.49 |
| ▸ | TEK | Q02763 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 12/20 | 0.47 |
| ▸ | RAF1 | P04049 | 10/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931696 | 0.91 | KDR (0.78) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL945594 | 0.90 | KDR (0.83) | KDRFLT1FLT4KDM1AAURKA | |
| SCHEMBL11931701 | 0.87 | KDR (0.69) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL11931690 | 0.82 | KDR (0.81) | KDRFLT1FLT4AURKAMET | |
| Fruquintinib SCHEMBL29516397 | 0.80 | KDR (1.00) | KDRFLT1FLT4AURKAMET | |
| Fruquintinib SCHEMBL947183 | 0.80 | KDR (1.00) | KDRFLT1FLT4AURKAMET | |
| Fruquintinib SCHEMBL29366206 | 0.80 | KDR (1.00) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL11931698 | 0.79 | KDR (0.83) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL29153407 | 0.79 | KDR (0.67) | KDRFLT1FLT4AURKAMET | |
| SCHEMBL30753465 | 0.79 | KDR (0.67) | KDRFLT1FLT4AURKAMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497372-B2 | Use of substituted quinazoline compounds in treating age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-07-30 | — | — | US | disclosed |
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2012-09-20 | — | — | US | disclosed |
| US-8212033-B2 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2012-07-03 | — | — | US | disclosed |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERRISES LIMITED | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238572-A1 | USE OF SUBSTITUTED QUINAZOLINE COMPOUNDS IN TREATING ANGIOGENESIS-RELATED DISEASES | FLT4, FLT1, CXCR4 | KDR 6/4885FLT1 2/4885FLT4 1/4885 |
| US-20110015213-A1 | QUINAZOLINE DERIVATIVES | FLT4, FLT1, ARG1 | KDR 4/4885FLT1 2/4885FLT4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.